ホーム > 市場調査レポート > 医薬品

市場調査レポート

商品コード

1085486

脊索腫治療薬の世界市場：薬剤クラス別、治療タイプ別、エンドユーザー別、地域別－規模、シェア、展望、機会分析（2022年～2028年）

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月06日 | 発行: Coherent Market Insights

| ページ情報: 英文 201 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 700,920円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,557,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

脊索腫の治療のための研究開発活動が活発化していることから、予測期間中の脊索腫治療薬市場の成長を牽引すると考えられます。

当レポートでは、世界の脊索腫治療薬市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。

ヒートマップ分析
市場シェア分析
- GlaxoSmithKline Plc
- デバイスポートフォリオ
- Bavarian Nordic
- デバイスポートフォリオ
- Boehringer Ingelheim International GmbH
- デバイスポートフォリオ
- Pfizer, Inc.
- デバイスポートフォリオ
- Merck &Co., Inc.
- デバイスポートフォリオ
- Sanofi SA
- デバイスポートフォリオ
- Astellas Pharma Inc.
- デバイスポートフォリオ
- AstraZeneca plc
- デバイスポートフォリオ
- Amgen, Inc.
- デバイスポートフォリオ
- Bristol-Myers Squibb and Company
- デバイスポートフォリオ
- Novartis International AG
- デバイスポートフォリオ
- Bayer AG
- デバイスポートフォリオ
- Dr. Reddy's Laboratories Ltd.
- デバイスポートフォリオ
- Mylan NV
- デバイスポートフォリオ
アナリストの見解

第6章セクション

Product Code: CMI3979

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.

Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.

Market Dynamics

The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.

Key features of the study:

This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chordoma disease therapeutics market based on the following parameters - company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy's Laboratories Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market

Detailed Segmentation:

Global Chordoma Disease Therapeutics Market, By Drug Class:
- Antimetabolites
- Anthracycline
- VEGFR Inhibitors
- EGFR Inhibitor
- Others
Global Chordoma Disease Therapeutics Market, By Treatment Type:
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Others
Global Chordoma Disease Therapeutics Market, By End User:
- Hospitals
- Clinics
- Oncology Centers
- Others
Global Chordoma Disease Therapeutics Market, By Region:
- North America
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Class:
  - Antimetabolites
  - Anthracycline
  - VEGFR Inhibitors
  - EGFR Inhibitor
  - Others
  - By Treatment Type
  - Chemotherapy
  - Targeted Therapy
  - Radiation Therapy
  - Others
  - By End User:
  - Hospitals
  - Clinics
  - Oncology Centers
  - Others
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- GlaxoSmithKline Plc *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Bavarian Nordic A/S
- Boehringer Ingelheim International GmbH
- Pfizer, Inc.
- Merck & Co., Inc.
- Sanofi SA
- Astellas Pharma Inc.
- AstraZeneca plc
- Amgen, Inc.
- Bristol-Myers Squibb and Company
- Novartis International AG
- Bayer AG
- Dr. Reddy's Laboratories Ltd.
- Mylan N.V.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Treatment Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Developments
PEST Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

Impact assessment
Pre COVID-19 Market Scenario
Post COVID-19 Market Scenario
Government measures to combat COVID-19

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Anthracycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
VEGFR Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
EGFR Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Radiation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

5. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- GlaxoSmithKline Plc
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bavarian Nordic
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi SA
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Astellas Pharma Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca plc
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb and Company
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis International AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Mylan N.V.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Analyst Views

6. Section

References
Research Methodology
About us and Sales Contact

ライセンス / 価格

PDF (Single User License)

USD 4,500 700,920円

PDF (Multi User License)

USD 7,000 1,090,320円

PDF (Enterprise User License)

USD 10,000 1,557,600円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

当社から購入するメリット

よくあるご質問

脊索腫治療薬の世界市場：薬剤クラス別、治療タイプ別、エンドユーザー別、地域別－規模、シェア、展望、機会分析（2022年～2028年）

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場の展望

第3章市場力学、規制、および動向分析

第4章世界の脊索腫治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第1章世界の脊索腫治療薬市場：薬剤クラス別（100万米ドル）（2021年～2028年）

第2章世界の脊索腫治療薬市場：治療タイプ別（100万米ドル）（2021年～2028年）

第3章世界の脊索腫治療薬市場：エンドユーザー別（100万米ドル）（2021年～2028年）

第4章世界の脊索腫治療薬市場：地域別（100万米ドル）（2021年～2028年）

第5章競合情勢

第6章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

5. Competitive Landscape

6. Section

脊索腫治療薬の世界市場：薬剤クラス別、治療タイプ別、エンドユーザー別、地域別－規模、シェア、展望、機会分析（2022年～2028年）

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場の展望

第3章 市場力学、規制、および動向分析

第4章 世界の脊索腫治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第1章 世界の脊索腫治療薬市場：薬剤クラス別（100万米ドル）（2021年～2028年）

第2章 世界の脊索腫治療薬市場：治療タイプ別（100万米ドル）（2021年～2028年）

第3章 世界の脊索腫治療薬市場：エンドユーザー別（100万米ドル）（2021年～2028年）

第4章 世界の脊索腫治療薬市場：地域別（100万米ドル）（2021年～2028年）

第5章 競合情勢

第6章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2017 - 2028, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2017 - 2028, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

5. Competitive Landscape

6. Section

第1章調査目的・前提条件

第2章市場の展望

第3章市場力学、規制、および動向分析

第4章世界の脊索腫治療薬市場 - コロナウイルス（COVID-19）パンデミックの影響

第1章世界の脊索腫治療薬市場：薬剤クラス別（100万米ドル）（2021年～2028年）

第2章世界の脊索腫治療薬市場：治療タイプ別（100万米ドル）（2021年～2028年）

第3章世界の脊索腫治療薬市場：エンドユーザー別（100万米ドル）（2021年～2028年）

第4章世界の脊索腫治療薬市場：地域別（100万米ドル）（2021年～2028年）

第5章競合情勢

第6章セクション